Novocure Ltd Aktie
Novocure Ltd Aktie
Was spricht für und gegen Novocure Ltd in den nächsten Jahren?
Pro
Kontra
Rendite von Novocure Ltd im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Novocure Ltd | -1,99 % | 11,71 % | 12,65 % | -76,47 % | 7,29 % | -89,79 % | - |
Ironwood Pharmaceuticals | - | -1,32 % | 1,35 % | -19,79 % | -26,47 % | -18,03 % | - |
Sage Therapeutics Inc. | 0,61 % | -14,74 % | -27,78 % | -76,98 % | -44,75 % | -82,13 % | - |
Iovance Biotherapeutics Inc. | -17,16 % | -19,68 % | -12,95 % | 46,35 % | 30,38 % | -53,35 % | - |
Kommentare
News
Novocure Reports First Quarter 2024 Financial Results
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed senior secured credit facility with funds managed by Pharmakon Advisors, LP. The
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of